

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 2017232554 B2**

(54) Title  
**Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production**

(51) International Patent Classification(s)  
**A23L 29/00** (2016.01)      **A61K 9/16** (2006.01)  
**A23L 33/115** (2016.01)      **A61K 9/20** (2006.01)  
**A23L 33/12** (2016.01)      **A61K 31/202** (2006.01)  
**A23P 10/28** (2016.01)      **A61K 35/60** (2006.01)  
**A23P 10/47** (2016.01)

(21) Application No: **2017232554**      (22) Date of Filing: **2017.03.15**

(87) WIPO No: **WO17/158439**

(30) Priority Data

(31) Number      (32) Date      (33) Country  
**62/309,013**      **2016.03.16**      **US**

(43) Publication Date: **2017.09.21**  
(44) Accepted Journal Date: **2020.05.14**

(71) Applicant(s)  
**Golden Omega Norway AS**

(72) Inventor(s)  
**Lien Vestland, Tina;Klaveness, Jo**

(74) Agent / Attorney  
**Spruson & Ferguson, GPO Box 3898, Sydney, NSW, 2001, AU**

(56) Related Art  
**WO 2008/146016 A2**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



WIPO | PCT



(10) International Publication Number

WO 2017/158439 A1

(43) International Publication Date

21 September 2017 (21.09.2017)

(51) International Patent Classification:

*A23L 29/00* (2016.01) *A61K 9/16* (2006.01)  
*A23P 10/28* (2016.01) *A61K 31/202* (2006.01)  
*A23P 10/47* (2016.01) *A61K 35/60* (2006.01)  
*A23L 33/115* (2016.01) *A61K 9/20* (2006.01)  
*A23L 33/12* (2016.01)

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/IB2017/000548

(22) International Filing Date:

15 March 2017 (15.03.2017)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/309,013 16 March 2016 (16.03.2016) US

(71) Applicant: OMEGATRI AS [NO/NO]; Nycoveien 2, Postboks 4849, 0422 Oslo (NO).

(72) Inventors: LIEN VESTLAND, Tina; C/o Omegatri As Nycoveien 2, Postboks, 0422 Oslo (NO). KLAVENESS, Jo; C/o Omegatri As Nycoveien 2, Postboks, 0422 Oslo (NO).

(74) Agent: JONES, J. Mitchell; Casimir Jones, S.C., 2275 Deming Way, Ste 310, Middleton, Wisconsin 53562 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2017/158439 A1

(54) Title: POWDERS AND TABLETS COMPRISING OMEGA-3 FATTY ACID DERIVATIVES AND METHODS FOR THEIR PRODUCTION

(57) Abstract: The present invention relates to methods of using surface active compounds(s) in the preparation process for powders comprising beta-cyclodextrin and omega-3 fatty acids and derivatives thereof and to the dry powders and tablets comprising surface active compounds(s) preferably diglycerides, beta-cyclodextrin and omega-3 fatty acids and derivatives thereof.

## **POWDERS AND TABLETS COMPRISING OMEGA-3 FATTY ACID DERIVATIVES AND METHODS FOR THEIR PRODUCTION**

### **FIELD OF THE INVENTION**

The present invention relates to an improved method for preparation of powder and tablets comprising omega-3 fatty acid derivatives and beta-cyclodextrin.

### **BACKGROUND OF THE INVENTION**

Omega-3 comprising products are generally provided either in the form of oil encapsulated in soft capsules or in the form of free oil (cod liver oil products). There has been a need for omega-3 products with different and improved properties relative to omega-3 in the form of oil. These improved properties are one or more of the following: improved oxidative stability, reduced fish taste typically from gastrointestinal reflux, efficient uptake from the gastrointestinal system, improved technical possibilities to prepare stable combination products (products comprising omega-3 plus one or more active components like minerals, vitamins, drug substances or food additives) and finally omega-3 products that can be used in food products like drinks (e.g. juice) and semisolid/solid food products (e.g. yoghurt and bread). Various forms of dry powders based on encapsulation of omega-3 droplets have been developed and these dry powders are extensively used in various drug products. These powders based on physical encapsulation of omega-3 oil do not have all the properties listed above and cannot be tableted due to the high pressure and increased temperature during tableting.

### **SUMMARY OF THE INVENTION**

A first aspect of the invention provides for a composition comprising:

a dry powder comprising beta-cyclodextrin in an amount of from 60% to 90% w/w of said powder and a lipid component in an amount of from about 10% to 40% w/w of said powder, wherein said lipid component comprises an omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, wherein said omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides

comprises EPA and DHA fatty acids at a concentration of from 10% to 99% w/w of the fatty acids in said omega-3 triglycerides, wherein said lipid component is characterized as having a surfactant content of from about 10% to 35% w/w of said lipid component, wherein said surfactant is a diglyceride of fatty acids.

5 A second aspect of the invention provides for a tableted lipid formulation comprising beta-cyclodextrin in a concentration of from 60% to 90% w/w of said tablet and a lipid component in a concentration of from 10% to 40% w/w of said tablet, wherein said lipid component comprises an omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, wherein said omega-3 fatty acid or derivative thereof  
10 selected from the group consisting of omega-3 triglycerides, comprises EPA and DHA fatty acids at a concentration of from 10% to 99% w/w of the fatty acids in said omega-3 triglycerides, wherein said lipid component is characterized as having a diglyceride content of from 10% to 35% w/w of said lipid component.

15 A third aspect of the invention provides for a process for making a tabletable lipid powder comprising:

20 combining an aqueous solution of beta-cyclodextrin with a lipid component in an amount of from 10% to 40% w/w of said beta-cyclodextrin said solution, wherein said lipid component comprises an omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, wherein said omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty acids at a concentration of from 10% to 99% w/ of the fatty acids in said omega-3 triglycerides, wherein said lipid component comprises one or more surfactants at a concentration of from 10% to 35% w/w of said lipid component, wherein said surfactant is a diglyceride of fatty acids;

25 mixing said aqueous solution of beta-cyclodextrin and said lipid component to provide a mixture; and

removing water from said mixture to provide a dry powder, preferably by spray granulating.

30 The present invention relates to an improved method for preparation of powder and tablets comprising omega-3 fatty acid derivatives and beta-cyclodextrin.

## 1b

Accordingly, in some embodiments, the present invention provides compositions comprising a dry powder comprising beta-cyclodextrin in an amount of from 60% to 90% w/w of the powder and a lipid component in an amount of from about 10% to 40% w/w of the powder, wherein the lipid component is characterized as having a surfactant content of 5 from about 0.1% to 35% w/w of the lipid component.

In some embodiments, the lipid component comprises an omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids. In some embodiments, wherein the omega-3 fatty acids or derivatives thereof have an EPA:DHA ratio of greater than 1:1. In some embodiments, the omega-3 fatty acids or derivatives thereof have a DHA:EPA ratio of greater than 1:1. In some embodiments, the omega-3 triglycerides are a marine oil. In some embodiments, the marine oil is selected from the group consisting of fish oil, squid oil and algal oil. In some embodiments, the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids comprises EPA and DHA fatty acids at a concentration of from 10% to 99% w/w of the fatty acids in the omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids. In some embodiments, the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids comprises EPA and DHA fatty acids at a concentration of from 10% to 70% w/w of the fatty acids in the omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids. In some embodiments, the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids comprises EPA and DHA fatty acids at a concentration of from 30% to 60% w/w of the fatty acids in the omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids.

In some embodiments, the surfactant is selected from the group consisting of mono- and diglycerides of fatty acids, sorbitan esters of fatty acids, and polysorbates and combinations thereof. In some embodiments, the surfactant is selected from the group consisting of mono- and diglycerides of fatty acids and combinations thereof. In some embodiments, the surfactant is a diglyceride of fatty acids. In some embodiments, the diglycerides of fatty acids comprise a mixture of diglyceride compounds wherein the fatty acid components of the diglycerides compounds are selected from saturated, monounsaturated and polyunsaturated fatty acids. In some embodiments, the polyunsaturated fatty acids are omega-3 fatty acids. In some embodiments, the omega-3 fatty acids are selected from EPA and DHA. In some embodiments, the concentration of the surfactant in the lipid component is from 10% to 35% w/w of the lipid component. In some

embodiments, the surfactant is not an added naturally occurring surfactant selected from the group consisting of naturally occurring phospholipids, triglycerides and free fatty acids or a salt or ester of a long chain omega-3 fatty acid.

5 In some embodiments, the powder composition is spray granulated. In some embodiments, the powder composition is spray granulated and has a particle size distribution of 50-650 microns. In some embodiments, the powder composition is spray granulated and has a particle size distribution of 200-500 microns.

10 In some embodiments, the present invention provides tableted lipid formulations comprising beta-cyclodextrin in a concentration of from 60% to 90% w/w of the tablet and a lipid component in a concentration of from 10% to 40% w/w of the tablet, wherein the lipid component is characterized as having a surfactant content of from 0.1% to 35% w/w of the lipid component, wherein the tablet has a crushing strength of greater than 3 kN.

15 In some embodiments, the tablet has a crushing strength of greater than 5 kN. In some embodiments, the tablet has a crushing strength of greater than 7 kN. In some embodiments, the tablet has a crushing strength of from 5 to 10 kN.

20 In some embodiments, the present invention provides tableted lipid formulations comprising beta-cyclodextrin in a concentration of from 60% to 90% w/w of the tablet and a lipid component in a concentration of from 10% to 40% w/w of the tablet, wherein the lipid component is characterized as having a diglyceride content of from 10% to 35% w/w of the lipid component, wherein the tablet has a crushing strength of greater than 3 kN.

In some embodiments, the tablet has a crushing strength of greater than 5 kN. In some embodiments, the tablet has a crushing strength of greater than 7 kN. In some embodiments, the tablet has a crushing strength of from 5 to 10 kN.

25 In some embodiments, the lipid component comprises an omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids. In some embodiments, the omega-3 fatty acids or derivatives thereof have an EPA:DHA ratio of greater than 1:1. In some embodiments, the omega-3 fatty acids or derivatives thereof have a DHA:EPA ratio of

greater than 1:1. In some embodiments, the omega-3 triglycerides are a marine oil. In some embodiments, the marine oil is selected from the group consisting of fish oil, squid oil and algal oil. In some embodiments, the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids comprises EPA and DHA fatty acids at a concentration of from 5 10% to 99% w/w of the fatty acids in the omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids. In some embodiments, the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids comprises EPA 10 and DHA fatty acids at a concentration of from 10% to 70% w/w of the fatty acids in the omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids. In some embodiments, the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids comprises EPA and DHA fatty acids at a concentration of from 15 30% to 60% w/w of the fatty acids in the omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids.

In some embodiments, the diglycerides comprise a mixture of diglyceride compounds wherein the fatty acid components of the diglycerides compounds are selected from saturated, monounsaturated and polyunsaturated fatty acids. In some embodiments, the 20 polyunsaturated fatty acids are omega-3 fatty acids. In some embodiments, omega-3 fatty acids are selected from EPA and DHA. In some embodiments, the tableted lipid formulation does not comprise an added naturally occurring surfactant selected from the group consisting of naturally occurring phospholipids, triglycerides and free fatty acids or a salt or ester of a long chain omega-3 fatty acid.

25 In some embodiments, the tableted formulation is coated. In some embodiments, the tableted formulation is coated with an agent selected from the group consisting of polyvinyl acetate, methyl acrylate-methacrylic acid copolymers, cellulose acetate phthalate (CAP), cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylic acid copolymers, cellulose acetate trimellitate, and sodium alginate.

In some embodiments, the lipid component is combined with an additional nutraceutical agent that is not an omega-3 fatty acid or derivative thereof. In some embodiments, the lipid component is combined with an additional pharmaceutical agent that is not an omega-3 fatty acid or derivative thereof.

5 In some embodiments, the present invention provides processes for making a tabletable lipid powder comprising: combining an aqueous solution of beta-cyclodextrin with a lipid component in an amount of from 10% to 40% w/w of the beta-cyclodextrin the solution, wherein the lipid component comprises one or more surfactants at a concentration of from 0.1% to 35% w/w of the lipid component; mixing the aqueous solution of beta-10 cyclodextrin and the lipid component to provide a mixture; and removing water from the mixture to provide a dry powder.

In some embodiments, the lipid component comprises an omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids. In some embodiments, the 15 omega-3 fatty acids or derivatives thereof have an EPA:DHA ratio of greater than 1:1. In some embodiments, the omega-3 fatty acids or derivatives thereof have a DHA:EPA ratio of greater than 1:1. In some embodiments, the omega-3 triglycerides are a marine oil. In some embodiments, the marine oil is selected from the group consisting of fish oil, squid oil and algal oil. In some embodiments, the omega-3 fatty acid or derivative thereof selected from 20 the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids comprises EPA and DHA fatty acids at a concentration of from 10% to 99% w/w of the fatty acids in the omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids. In some embodiments, the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids 25 and salts of omega-3 fatty acids comprises EPA and DHA fatty acids at a concentration of from 10% to 70% w/w of the fatty acids in the omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids. In some embodiments, the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids 30 and salts of omega-3 fatty acids comprises EPA and DHA fatty acids at a concentration of from

20% to 45% w/w of the fatty acids in the omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids.

In some embodiments, the surfactant is selected from the group consisting of selected among mono- and diglycerides of fatty acids, sorbitan esters of fatty acids, and 5 polysorbates and combinations thereof. In some embodiments, the surfactant is selected from the group consisting of mono- and diglycerides of fatty acids and combinations thereof. In some embodiments, the surfactant is a diglyceride of fatty acids. In some embodiments, the diglycerides of fatty acids comprise a mixture of diglyceride compounds wherein the fatty acid components of the diglycerides compounds are selected from saturated, 10 monounsaturated and polyunsaturated fatty acids. In some embodiments, the polyunsaturated fatty acids are omega-3 fatty acids. In some embodiments, the omega-3 fatty acids are selected from EPA and DHA. In some embodiments, the concentration of the surfactant in the lipid component is from 10% to 35% w/w of the lipid component. In some embodiments, the surfactant is not an added naturally occurring surfactant selected from the 15 group consisting of naturally occurring phospholipids, triglycerides and free fatty acids or a salt or ester of a long chain omega-3 fatty acid.

In some embodiments, the removing water from the mixture to provide a dry powder further comprises spray drying. In some embodiments, the removal of water is performed as spray granulation and the powder has a particle size distribution of 50-650 microns. In some 20 embodiments, the removal of water is performed as spray granulation and the powder has a particle size distribution of 200-500 microns.

In some embodiments, the processes further comprise the step of forming a tablet from the dry powder. In some embodiments, the tablet has a crushing strength of greater than 5 kN. In some embodiments, the tablet has a crushing strength of greater than 7 kN. In 25 some embodiments, the tablet has a crushing strength of from 5 to 10 kN.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the method to use surface active compounds(s), preferably diglycerides, in the preparation process for powders comprising beta-cyclodextrin and omega-3 fatty acids and derivatives thereof and to the dry powders and tablets

comprising surface active compounds(s), preferably diglycerides, beta-cyclodextrin and omega-3 fatty acids and derivatives thereof.

The inventors unexpectedly observed that the addition of between 10% and 35% diglycerides to an omega-3 oil composition (% weight/weight (w/w) calculated as weight of 5 diglycerides divided by the total weight of the diglycerides plus the weight of the oil) allowed for the production of a beta-cyclodextrin powder with superior tabletting properties as well as tablets with superior properties.

The most preferred diglycerides for use in the present invention comprise a mixture of 10 diglyceride compounds, where the fatty acid components in the mixture of diglyceride molecules can be saturated, monounsaturated and/or polyunsaturated, including omega-3 fatty acids like EPA and DHA.

The diglyceride molecules typically comprise saturated, monounsaturated and/or 15 polyunsaturated fatty acids of various number of carbon atoms and various number of double bonds. Some typical fatty acids include fatty acids belonging to one or more of the following groups of fatty acids: 14:0, 15:0, 16:0, 16: 1, 17:0, 18:0, 18: 1, 18:2, 18 :3, 18: 4, 20: 1, 20: 4, 20:5, 22: 1, 22:5 and 22:6. The first number represents the number of carbon atoms and the last number represents the number of double bonds. EPA belongs to the fatty acid group 20:5 with 20 carbon atoms and 5 double bonds, while DHA belongs to the fatty acid group 22:6 with 22 carbon atoms and 6 double bonds. Both EPA and DHA have cis (Z)-isomer double 20 bonds.

The diglycerides described according to the present invention might be naturally 25 present in the oil or present in the oil as a result of the production process. The diglyceride might also be added to the oil before processing to a tabletable powder. In any event, the diglyceride content of the oil is adjusted to be in the range of from 10% to 35% of the weight of the oil on a w/w basis.

The diglyceride can be in the form of 1,2-diacylglycerols and/or 1,3-diacylglycerols. Diglycerides of fatty acids are approved food additives as emulsifiers. The diglycerides preferably have an HLB of about 3.

One of the most preferred aspects of the present invention is to use oil comprising a mixture of diglycerides where one or more of the single diglyceride molecular components are diglycerides with one or two EPA fatty acids or diglycerides with one or two DHA fatty acids.

5 If one component in the diglyceride mixture is a diglyceride with EPA, the other fatty acid might typically be an acid selected among the following groups of fatty acids: 14:0, 15:0, 16:0, 16: 1, 17:0, 18:0, 18: 1, 18:2, 18 :3, 18: 4, 20: 1, 20: 4, 20:5, 22: 1, 22:5 and 22:6.

If one component in the diglyceride mixture is a diglyceride with DHA, the other fatty acid might typically be an acid selected among the following groups of fatty acids: 14:0, 15:0, 16:0, 16: 1, 17:0, 18:0, 18: 1, 18:2, 18 :3, 18: 4, 20: 1, 20: 4, 20:5, 22: 1, 22:5 and 22:6.

10 The inclusion of such surfactant(s), preferably diglycerides, improve(s) the quality of the powder both with regard to stability and tableting. The present invention therefore relates to methods for preparation of powder and tablets comprising omega-3 fatty acid derivatives and beta-cyclodextrin and products prepared by the method. The method is characterized by including of one or more surface active compounds preferably diglycerides during preparation of the aqueous slurry before preparation of the dry powder. The surfactant will generally be present in the powder and thereby the tablets. Aspects of the present invention are therefore powders and tablets comprising omega-3 fatty acid derivatives, beta-cyclodextrin and one or more surface active compounds. In some preferred 15 embodiments, the surface active agent is not a phospholipid and in further preferred embodiments, the powders contain less than 10%, 5%, 1% or 0.1% w/w total phospholipids. The method to use surface active compound(s) in the preparation process for powders comprising beta-cyclodextrin and omega-3 is new and the obtained powders showed unexpected improved properties. Dry powders and tablets comprising omega-3 fatty acids 20 and derivatives thereof, beta-cyclodextrin, and surface active compound(s) preferably diglycerides are also new.

25 The description below describes the following aspects of the present invention: (1) Method; (2) Powder prepared according to the method; and (3) Tablets comprising omega-3, cyclodextrin and surfactants, preferably diglycerides.

## 1. Method

One aspect of the present invention relates to a method for preparation of dry powder comprising omega-3, beta-cyclodextrin using a surfactant preferably diglycerides. A preferred aspect of the method is a method for preparation of dry powder comprising 5 omega-3, beta-cyclodextrin using a surfactant, preferably diglycerides, where the dry powder is a tabletable powder. A more preferred aspect of this aspect of method is a method for preparation of dry powder comprising omega-3, beta-cyclodextrin using a surfactant, preferably diglycerides, where the dry powder is a tabletable powder that can be tableted using standard tableting equipment producing more than 10,000 tablets per hour and the 10 tablets can be prepared continuously for hours.

In preferred embodiments, beta-cyclodextrin, one or more omega-3 fatty acid and derivatives thereof, and a surfactant, preferably diglycerides, are combined in an aqueous mixture. The mixture is agitated, for example by stirring, for a period of from about 5 minutes to 300 minutes, preferably from about 30 to about 90 minutes, and most preferably 15 for about 60 minutes. The water is then removed from the mixture, for example by evaporation under reduced pressure to yield a dry, tabletable powder. In some embodiments, the water is preferably removed by spray drying or granulation. In some embodiments, the powder has a particle size distribution of 50-650 microns, and most preferably from 200-500 microns, following spray drying or granulation.

20 In some embodiments, from 5% to 40%, 10% to 40%, 20% to 40%, 30% to 40%, 5% to 35%, 10% to 35%, 20% to 35%, 25% to 35%, 30% to 35%, at least 5%, at least 10%, at least 20%, at 30% or at least 35% w/w of an oil component is combined with the beta-cyclodextrin, wherein w/w refers to the total weight of the oil component to the total weight of beta-cyclodextrin. The w/w% above includes the weight of surfactant (e.g., a diglycerides) in the oil 25 used according to the present invention. In some embodiments, the oil component preferably comprises one or more omega-3 fatty acids or derivatives thereof. In some embodiments, the one or more omega-3 fatty acids or derivatives thereof are selected from omega-3 triglycerides, omega-3 ethyl esters, free omega-3 acids and/or pharmaceutically acceptable or food acceptable quality omega-3 fatty acid salts, alone or in combination. In 30 some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are the

main omega-3 components used to prepare the dry powder. In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are the main oil components used to prepare the dry powder (e.g., the oil component used in the process comprises greater than about 60%, 70%, 80%, 90%, or 95% w/w of the specified omega-3 fatty acid or derivative thereof (omega-3 triglycerides, omega-3 ethyl esters, free omega-3 acids and/or pharmaceutically acceptable or food acceptable quality omega-3 fatty acid salts) wherein w/w refers to the total weight of the specified omega-3 fatty acid or derivative thereof per the total weight of the oil component). In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are from a marine source, such as fish, algae, or have been prepared from raw products from fish or algae. In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are from plants or vegetables or have been prepared from raw products from plants and vegetables.

In some embodiments, the lipid component used to prepare the dry powder is an omega-3 composition. In some embodiments, the dry powder is prepared with omega-3 triglycerides. In some embodiments, the dry powder is prepared with omega-3 ethyl esters. In some embodiments, the dry powder is prepared with free omega-3 acids. In some embodiments, the dry powder is prepared with pharmaceutically acceptable or food acceptable quality of omega-3 fatty acid salts. In some embodiments, the omega-3 fatty acids or derivatives are preferably selected from EPA and DHA and combinations thereof. In some embodiments, the omega 3 fatty acids and derivatives thereof comprise more EPA than DHA. In some embodiments, the omega 3 fatty acids and derivatives thereof comprise more DHA than EPA. In some embodiments, the omega 3 fatty acids and derivatives thereof (e.g., triglycerides, ethyl esters, free acids or salts thereof, alone or in combination) comprise are enriched for EPA, e.g., more than 90% w/w of the total omega 3 fatty acids and derivatives thereof in the powder is EPA where the w/w% is the weight of EPA per total weight of fatty acids in the powder. In some embodiments, the omega 3 fatty acids and derivatives thereof (e.g., triglycerides, ethyl esters, or free acids) are enriched for DHA, e.g., more than 90% w/w of the total omega 3 fatty acids and derivatives thereof in the powder is DHA where the w/w% is the weight of DHA per total weight of fatty acids in the powder. In some embodiments, the lipid component preferably comprises from about 30% to 60% w/w EPA and/or DHA.

In some preferred embodiments, from 0.1% to 10% w/w, 0.1% to 20% w/w, 0.1% to 30% w/w, 1% to 10% w/w, 1% to 20% w/w, 1% to 30% w/w, 2% to 10% w/w, 2% to 20% w/w, 2% to 30% w/w, 5% to 10% w/w, 5% to 20% w/w, 5% to 30% w/w, 10% to 20% w/w, 10% to 30% w/w, 15% to 30% w/w, 18% to 30% w/w, 20% to 30% w/w surfactant or combination of

5 surfactants is included with the oil component, wherein w/w refers to the total weight of surfactant (or combination thereof) to the total weight of the oil component. In some embodiments, the surfactant is a surfactant approved for use for preparation of pharmaceutical products and or approved for use in food products. In some embodiments, the surfactant is a surfactant approved for use for preparation of pharmaceutical products. In

10 some embodiments, the surfactant is a surfactant approved for use for preparation of approved for use in food products. In some embodiments, the surfactant is a ionic surfactant; preferably a negatively charged surfactant. In some embodiments, the surfactant is a non-ionic surfactant. In some embodiments, the surfactant is a naturally occurring surfactant. In some embodiments, the surfactant is a surfactant produced synthetically or partly produced

15 synthetically. In some embodiments, the surfactant is a derivative of a fatty acid. In some embodiments, the surfactant is a derivative of glycerol. In some embodiments, the surfactant is selected among substances that are permitted to be used as food additives for use within the European Union, US or Asia. In some embodiments, the surfactant is selected among substances listed on the GRAS list. In some embodiments, the surfactant is selected among

20 the following compounds: E 400 alginic acid, E401 sodium alginate, E402 potassium alginate, E403 ammonium alginate, E404 calcium alginate, E430 polyoxyethene (8) stearate, E431 polyoxyethene (40) stearate, E432 polyoxyethene (20) sorbitan monolaurate (polysorbate 20), E433 polyoxyethene (20) sorbitan monooleate (polysorbate 80), E434 polyoxyethene (20) sorbitan monopalmitate (polysorbate 40), E435 polyoxyethene (20) sorbitan monostearate

25 (polysorbate 60), E436 polyoxyethene (20) sorbitan tristearate (polysorbate 65), E470a sodium, potassium and calcium salts of fatty acids, E470b magnesium salts of fatty acids, E471 mono- and diglycerides of fatty acids (glyceryl monostearate, glyceryl distearate) and other monoglycerides of fatty acids and diglycerides of fatty acids, E472 acetic acid esters of mono- and diglycerides of fatty acids, E472b lactic acid esters of mono- and diglycerides of

30 fatty acids, E472c citric acid esters of mono- and diglycerides of fatty acids, E472d tartaric acid esters of mono- and diglycerides of fatty acids, E472e mono- and diacetyl tartaric acid esters of mono- and diglycerides of fatty acids, E472f mixed acetic and tartaric acid esters of mono-

and diglycerides of fatty acids, E472g succinylated monoglycerides, E473 sucrose esters of fatty acids, E474 sucroglycerides, E475 polyglycerol esters of fatty acids, E476 polyglycerol polyricinoleate, E477 propane-1,2-diol esters of fatty acids, propylene glycol esters of fatty acids, E478 lactylated fatty acid esters of glycerol and propane-1, E479b thermally oxidized soya bean oil interacted with mono- and diglycerides of fatty acid, E480 dioctyl sodium sulphosuccinate, E481 sodium stearoyl-2-lactylate, E482 calcium stearoyl-2-lactylate, E483 stearyl tartrate, E484 stearyl citrate, E485 sodium stearoyl fumarate, E486 calcium stearoyl fumarate, E487 sodium laurylsulphate, E488 ethoxylated mono- and di-glycerides, E489 methyl glucoside-coconut oil ester, E490 propane-1,2-diol, E491 sorbitan monostearate, E492 sorbitan tristearate, E493 sorbitan monolaurate, E494 sorbitan monooleate, E495 sorbitan monopalmitate, E496 sorbitan trioleate, E497 polyoxypropylene-polyoxyethylene polymers and E498 partial polyglycerol esters of polycondensed fatty acids of castor oil. The term fatty acid includes any natural saturated fatty acids, monounsaturated fatty acids and polyunsaturated fatty acids and mixtures thereof.

15 In some embodiments, the surfactant or a surfactant mixture that has a HLB value of from 1 to 20. The HLB (Hydrophilic Lipophilic Balance) value for a given surfactant is measure of the degree to which the surfactant is hydrophilic or lipophilic. The figure is dependent on which functional groups that are present in the surfactant molecule and where in the molecule these functional groups are located. Surfactants with HLB value of less than 10 are 20 soluble in lipids, while surfactants with HLB values higher than 10 are soluble in water. The HLB values of the various surfactants are available from various commercial and scientific sources; see for example Surfactants Classified by HLB Numbers on sigmaaldrich.com or basic teaching books in pharmaceutical sciences like A.T. Florence and D. Attwood: Physicochemical Principles of Pharmacy, Pharmaceutical Press, 2004 on page 240. The HLB value for some 25 preferred surfactants according to the present invention are: mono-and diglycerides (HLB = appr.2-5 (depending on ratio, the more diglyceride the lower HLB value)), sorbitan esters HLB values around 4-5 (sorbitan oleate HLB = 4.3, sorbitan monostearate HLB = 4.7, sorbitan stearate HLB = 4.7) and polysorbates HLB values around 15.

30 In some preferred embodiments, the surfactant is selected among mono- and diglycerides of fatty acids, sorbitan esters with fatty acids and polysorbates or mixtures thereof. In some embodiments, the surfactant is not a phospholipid and most preferably is

not a naturally occurring phospholipid. In some embodiments, the surfactant is not a triglyceride and most preferably is not a naturally occurring triglyceride. In some embodiments, the surfactant is not a free fatty acid and most preferably is not a naturally occurring free fatty acid. In some preferred embodiments, the surfactant is not a salt or ester 5 of EPA, DHA or other long chain (greater than 20 carbons) omega-3 fatty acid.

The more preferred surfactants are diglycerides and the most preferred surfactants are diglycerides where one or more of the acids are omega-3 fatty acids. In especially preferred embodiments, the diglycerides comprise of a mixture of diglyceride compounds where the fatty acid components in the mixture of diglyceride molecules can be saturated, 10 monounsaturated and polyunsaturated including omega-3 fatty acids like EPA and DHA.

A person skilled in the art would expect based on the unexpectedly good results with omega-3 oils comprising diglyceride for preparation of tabletable powder and tablets that other surfactants or surfactant mixtures with similar HLB-values will be as helpful as diglycerides.

15 In some embodiments, the lipid component preferably comprises an omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, omega-3 ethyl esters, omega-3 free fatty acids and salts of omega-3 fatty acids. However, in some embodiments, additional active ingredients may be included in the lipid component along with omega-3 fatty acids or derivatives thereof. Suitable additional active ingredients 20 include, but are not limited to other active fatty acids such as omega-6 fatty acids, conjugated fatty acids such as conjugated linoleic acid fatty acid, and lipophilic drugs such as Class II and Class IV drugs as classified under the Biopharmaceutics Classification System. Indeed, a variety a nutraceutical and pharmaceutical agents may be included in the lipid component. In some preferred embodiments, the nutraceutical and pharmaceutical agents are lipophilic.

25 In some embodiments, the active ingredient is a pharmaceutical ingredient selected from the groups consisting of antineoplastic, antifungal, antiviral, anticonvulsant, antiepileptic, immunosuppressant, and erectile dysfunction drugs. The BCS is a guide for predicting the intestinal drug absorption provided by the U.S. Food and Drug Administration. This system restricts the prediction using the parameters solubility and intestinal 30 permeability. According to the Biopharmaceutics Classification System, drug substances are

classified as follows: Class I –high permeability, high solubility (compounds are well absorbed at all GI PH and their absorption rate is usually higher than excretion); Class II- high permeability, low solubility (bioavailability of those products is limited by their solubility and rate of dissolution Class III - low permeability, high solubility (absorption is limited by the 5 permeation rate but the drug is solvated very fast; if the formulation does not change the permeability or gastro-intestinal duration time, then class I criteria can be applied); Class IV - low permeability, low solubility (compounds have a poor bioavailability; usually they are not well absorbed over the intestinal mucosa and a high variability is expected).

The drugs are classified in BCS on the basis of following parameters: 1. Solubility;

10 2. Permeability; and 3. Rate of dissolution. Solubility class boundaries are based on the highest dose strength of an immediate release product. A drug is considered highly soluble when the highest dose strength is soluble in 250ml or less of aqueous media over the ph range of 1 to 7.5. The volume estimate of 250ml is derived from typical bioequivalence study protocols that prescribe administration of a drug product to fasting human volunteers with a glass of water.

15 Permeability class boundaries are based indirectly on the extent of absorption of a drug substance in humans and directly on the measurement of rates of mass transfer across human intestinal membrane. Alternatively non-human systems capable of prediction the drug absorption systems capable of predicting the drug absorption in humans can be used (such as in-vitro culture methods). A drug substance is considered highly permeable when the extent 20 of absorption in humans is determined to be 90% or more of the administered dose based on a mass-balance determination or in comparison to an intravenous dose. With respect to dissolution class boundaries, an immediate release product is considered rapidly dissolving when no less than 85% of the labeled amount of the drug substance dissolve within 15 minutes using USP Dissolution Apparatus 1 at 100 RPM or Apparatus 2 at 50 RPM in a volume 25 of 900ml or less in following media,) 0.1 N HCl or simulated gastric fluid or pH 4.5 buffer and pH 6.8 buffer or simulated intestinal fluid.

In some embodiments, the additional active ingredient is a drug including, but not limited to the following drugs: tripranavir, cediranib, pivoxil, tadalafil, mycophenolic acid, posaconazole, lapatinib, bromocriptine, ticagrelor, sorafenib, itraconazole, erlotinib, 30 sirolimus, alvimopan, naltrexone, vardenafil, rosuvastatin, maraviroc, ritonavir, efavirez, celecoxib, atovaquone, raloxifene, finasteride, everolimus, and dodrenarone.

In some embodiments, the additional active ingredient is selected from the groups consisting of antineoplastic, antifungal, antiviral, anticonvulsant, antiepileptic, antidepressant, immunosuppressant, anti-inflammatory and erectile dysfunction drugs.

In some embodiments, exemplary antineoplastic drugs suitable for use as an additional active ingredient include, but are not limited to: 1) alkaloids, including microtubule inhibitors (e.g., vincristine, vinblastine, and vindesine, etc.), microtubule stabilizers (e.g., paclitaxel (TAXOL), and docetaxel, etc.), and chromatin function inhibitors, including topoisomerase inhibitors, such as epipodophyllotoxins (e.g., etoposide (VP-16), and teniposide (VM-26), etc.), and agents that target topoisomerase I (e.g., camptothecin and 5 isirinotecan (CPTII), etc.); 2) covalent DNA-binding agents (alkylating agents), including nitrogen mustards (e.g., mechlorethamine, chlorambucil, cyclophosphamide, ifosfamide, and busulfan (MYLERAN), etc.), nitrosoureas (e.g., carmustine, lomustine, and semustine, etc.), and other alkylating agents (e.g., dacarbazine, hydroxymethylmelamine, thiotepe, and mitomycin, etc.); 3) noncovalent DNA-binding agents (antitumor antibiotics), including nucleic acid inhibitors (e.g., dactinomycin (actinomycin D), etc.), anthracyclines (e.g., daunorubicin (daunomycin, and cerubidine), doxorubicin (adriamycin), and idarubicin (idamycin), etc.), anthracenediones (e.g., anthracycline analogues, such as mitoxantrone, etc.), bleomycins (BLENOXANE), etc., and plicamycin (mithramycin), etc.; 4) antimetabolites, including antifolates (e.g., methotrexate, FOLEX, and MEXATE, etc.), purine antimetabolites (e.g., 6-20 mercaptourine (6-MP, PURINETHOL), 6-thioguanine (6-TG), azathioprine, acyclovir, ganciclovir, chlorodeoxyadenosine, 2-chlorodeoxyadenosine (CdA), and 2'-deoxycoformycin (pentostatin), etc.), pyrimidine antagonists (e.g., fluoropyrimidines (e.g., 5-fluorouracil (ADRUCIL), 5-fluorodeoxyuridine (FdUrd) (floxuridine)) etc.), and cytosine arabinosides (e.g., CYTOSAR (ara-C) and fludarabine, etc.); 5) enzymes, including L-asparaginase, and 25 hydroxyurea, etc.; and 6) platinum compounds (e.g., cisplatin and carboplatin, etc.).

In some embodiments, exemplary antifungal drugs suitable for use as an additional active ingredient include, but are not limited to nystatin, amphotericin B, griseofulvin, miconazole, ketoconazole, terbinafine, itraconazole, fluconazole, posaconazole, and voriconazole. In some embodiments, exemplary antiviral drugs suitable for use in dosage forms of the present invention include, but are not limited to abacavir, aciclovir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, boceprevir,

cidofovir, combivir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fomivirsen, fosamprenavir, foscamet, fosfonet, ganciclovir, ibacicabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, lamivudine, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, 5 nexavir, oseltamivir (Tamiflu), peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin, raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, stavudine, tea tree oil, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir (Valtrex), valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, zanamivir (Relenza) and zidovudine.

10 In some embodiments, exemplary anticonvulsant drugs suitable for use as an additional active ingredient include, but are not limited to pregabalin, gabapentin, carbamazepine, and oxcarbazepine.

15 In some embodiments, exemplary antiepileptic and anticonvulsant drugs suitable for use as an additional active ingredient include, but are not limited to pregabalin, gabapentin, carbamazepine, and oxcarbazepine and alprazolam, bretazenil, bromazepam, brotizolam, chlordiazepoxide, cinolazepam, clonazepam, clorazepate, clotiazepam, cloxazolam, delorazepam, diazepam, estazolam, etizolam, flunitrazepam, flurazepam, flutoprazepam, halazepam, ketazolam, loprazolam, lorazepam, lormetazepam, medazepam, midazolam, nemetazepam, nitrazepam, nordazepam, oxazepam, phenazepam, pinazepam, prazepam, 20 premazepam, quazepam, temazepam, tetrazepam, triazolam, clobazam, DMCM, flumazenil, eszopiclone, zaleplon, zolpidem, and zopiclone.

25 In some embodiments, exemplary antidepressant drugs suitable for use as an additional active ingredient include, but are not limited to tricyclic compounds such as bupropion, nortriptyline, desipramine, amitriptyline, amitriptylinoxide, butriptyline, clomipramine, demexiptiline, dibenzepin, dimetacrine, dosulepin/dothiepin, doxepin, imipramine, amineptine, iprindole, opipramol, tianeptine, trimipramine, imipraminoxide, lofepramine, melitracin, metapramine, nitroxazepam, noxiptiline, pipofezine, propizepine, protriptyline, and quinupramine; SNRIs such as duloxetine, venlafaxine, desvenlafaxine, milnacipran, levomilnacipran, sibutramine, bicifadine, and SEP-227162; and SSRIs such as

citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, indalpin, paroxetine, sertraline, and zimelidine.

In some embodiments, exemplary immunosuppressant drugs suitable for use as an additional active ingredient include, but are not limited to azathioprine, mycophenolic acid, 5 leflunomide, teriflunomide, methotrexate, tacrolimus, cyclosporin, pimecrolimus, abetimus, gusperimus, thalidomide, lenalidomide, anakinra, sirolimus, everolimus, ridaforolimus, tesirolimus, umirolimus, and zotarolimus.

In some embodiments, exemplary erectile dysfunction drugs suitable for use as an additional active ingredient include, but are not limited to Tadalafil, Vardenafil, Sildenafil, 10 Alprostadil, Papaverine, and Phentolamine.

In some embodiments, the additional active ingredient is a non-steroidal anti-inflammatory drugs (NSAIDS). The NSAIDS can, for example, be selected from the following: choline salicylate (Arthropan) celecoxib (Celebrex); diclofenac potassium (Cataflam); diclofenac sodium (Voltaren, Voltaren XR); diclofenac sodium with misoprostol (Arthrotec); 15 diflunisal (Dolobid); etodolac (Lodine, Lodine XL); fenoprofen calcium (Nalfon); flurbiprofen (Ansaid); ibuprofen (Advil, Motrin, Motrin IB, Nuprin); indomethacin (Indocin, Indocin SR); ketoprofen (Actron, Orudis, Orudis KT, Oruvail); magnesium salicylate (Arthritab, Bayer Select, Doan's Pills, Magan, Mobidin, Mobogesic); meclofenamate sodium (Meclofenam); mefenamic acid (Ponstel); meloxicam (Mobic); nabumetone (Relafen); naproxen (Naprosyn, Naprelan); 20 naproxen sodium (Aleve, Anaprox); oxaprozin (Daypro); piroxicam (Feldene); rofecoxib (Vioxx); salsalate (Amigesic, Anaflex 750, Disalcid, Marthritic, Mono-Gesic, Salflex, Salsitab); sodium salicylate (various generics); sulindac (Clinoril); tolmetin sodium (Tolectin); and valdecoxib (Bextra).

25 **2. Powders**

Another aspect of the present invention relates to powders prepared by the methods described above. In some embodiments, the dry powders of the present invention are tabletable powders. In some embodiments, the dry powders of the present invention can be

tableted using standard tableting equipment producing more than 10,000 tablets per hour and the tablets can be prepared continuously for hours.

The present powder is prepared from the aqueous mixture by removing the water. The process for preparation of dry powder include various state of the art methods within 5 pharmaceutical production like drying at increased temperature, vacuum drying, freeze drying, spray drying and spray granulation. Spray drying/spray granulation methods are the most preferred methods for preparation of tablettable powder.

In some embodiments, the powders of the present invention comprise an oil component and beta-cyclodextrin in a defined ratio which may preferably be expressed as a 10 weight/weight (w/w) percentage of the oil component in the powder. In some embodiments, the powders of the present invention therefore comprise from 5% to 40%, 10% to 40%, 20% to 40%, 30% to 40%, 5% to 35%, 10% to 35%, 20% to 35%, 25% to 35%, 30% to 35%, at least 5%, at least 10%, at least 20%, at 30% or at least 35% w/w of an oil component, wherein w/w refers to the total weight of the oil component to the total weight 15 of the powder.

In some embodiments, the oil component preferably comprises one or more omega-3 fatty acids or derivatives thereof. In some embodiments, the one or more omega-3 fatty acids or derivatives thereof are selected from omega-3 triglycerides, omega-3 ethyl esters, free omega-3 acids and/or pharmaceutically acceptable or food acceptable quality omega-3 20 fatty acid salts, alone or in combination. In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are the main omega-3 components used to prepare the dry powder. In some embodiments, the one or more omega-3 fatty acids or derivatives thereof are selected from omega-3 triglycerides, omega-3 ethyl esters, free omega-3 acids and/or pharmaceutically acceptable or food acceptable quality omega-3 fatty acid salts, alone 25 or in combination. In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are the main omega-3 components in the dry powder. In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are the main oil components in the dry powder (e.g., the oil component in the powder comprises greater than about 70%, 80%, 90%, or 95% w/w of the specified omega-3 fatty acid or derivative 30 thereof (omega-3 triglycerides, omega-3 ethyl esters, free omega-3 acids and/or

pharmaceutically acceptable or food acceptable quality omega-3 fatty acid salts) wherein w/w refers to the total weight of the specified omega-3 fatty acid or derivative thereof per the total weight of the oil component). In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are from a marine source, such as fish, algae, or have been prepared from raw products from fish or algae. In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are from plants or vegetables or have been prepared from raw products from plants and vegetables. In some embodiments, the lipid component preferably comprises from about 30% to 60% w/w EPA and/or DHA. In some embodiments, the lipid component, and thus the powders, may comprise an additional active 5 ingredient as described in detail above.

10

In some embodiments, the dry powder comprises omega-3 triglycerides. In some embodiments, the dry powder comprises omega-3 ethyl esters. In some embodiments, the dry powder comprises free omega-3 acids. In some embodiments, the dry powder comprises pharmaceutically acceptable or food acceptable quality of omega-3 fatty acid salts. In some 15 embodiments, the omega-3 fatty acids or derivatives are preferably selected from EPA and DHA and combinations thereof. In some embodiments, the omega 3 fatty acids and derivatives thereof comprise more EPA than DHA (i.e., the ratio of EPA: DHA is greater than 1:1). In some embodiments, the omega 3 fatty acids and derivatives thereof comprise more DHA than EPA (i.e., the ratio of DHA: EPA is greater than 1:1). In some embodiments, the 20 omega 3 fatty acids and derivatives thereof (e.g., triglycerides, ethyl esters, free acids or salts thereof, alone or in combination) comprise are enriched for EPA, e.g., more than 90% w/w of the total omega 3 fatty acids and derivatives thereof in the powder is EPA where the w/w is the weight of EPA per total weight of fatty acids in the powder. In some embodiments, the omega 3 fatty acids and derivatives thereof (e.g., triglycerides, ethyl esters, or free acids) are 25 enriched for DHA, e.g., more than 90% w/w of the total omega 3 fatty acids and derivatives thereof in the powder is DHA where the w/w% is the weight of DHA per total weight of fatty acids in the powder.

In some embodiments, the powders may be further characterized according to their total omega-3 content. In some embodiments, the dry powders of the present invention 30 comprise more than 5 % w/w, more than 10% w/w, more than 15% w/w, more than 20% w/w, more than 25% w/w or more than 30% w/w of omega-3 triglycerides, omega-3 ethyl

esters, free omega-3 acids and/or pharmaceutically acceptable or food acceptable quality of omega-3 fatty acid salts where w/w refers to the total weight of the omega-3 triglycerides, omega-3 ethyl esters, free omega-3 acids and/or pharmaceutically acceptable or food acceptable quality of omega-3 fatty acid salts per the total weight of the powder.

5        In some embodiments, the dry powders of the present invention comprise a surfactant (e.g., a diglycerides composition). In some embodiments, the w/w percent of the surfactant in the dry powder may be less than the w/w percent of surfactant used to prepare the powder, especially where the surfactant is water soluble. The surfactant or combination of surfactants is preferably included in the powder in a defined ratio as compared to the oil  
10      component.

Accordingly, in some embodiments, the dry powders of the present invention comprise a surfactant (e.g., a diglycerides composition) in a defined ratio to the amount of the oil component, preferably from 0.1% to 10% w/w, 0.1% to 20% w/w, 0.1% to 30% w/w, 1% to 10% w/w, 1% to 20% w/w, 1% to 30% w/w, 2% to 10% w/w, 2% to 20% w/w, 2% to 30%  
15      w/w, 5% to 10% w/w, 5% to 20% w/w, 5% to 30% w/w, 10% to 20% w/w, 10% to 30% w/w, 15% to 30% w/w, 18% to 30% w/w, 20% to 30% w/w, or 10% to 35% w/w surfactant or  
20      combination of surfactants, wherein w/w refers to the total weight of surfactant (or  
25      combination thereof) to the total weight of the oil component including the surfactant.

In some embodiments, the surfactant is a surfactant approved for use for preparation  
20      of pharmaceutical products and or approved for use in food products. In some embodiments, the surfactant is a surfactant approved for use for preparation of pharmaceutical products. In some embodiments, the surfactant is a surfactant approved for use for preparation of  
25      approved for use in food products. In some embodiments, the surfactant is a ionic surfactant; preferably a negatively charged surfactant. In some embodiments, the surfactant is a non-  
30      ionic surfactant. In some embodiments, the surfactant is a naturally occurring surfactant. In some embodiments, the surfactant is a surfactant produced synthetically or partly produced synthetically. In some embodiments, the surfactant is a derivative of a fatty acid. In some  
35      embodiments, the surfactant is a derivative of glycerol. In some embodiments, the surfactant is selected among substances that are permitted to be used as food additives for use within  
40      the European Union, US or Asia. In some embodiments, the surfactant is selected among

substances listed on the GRAS list. In some embodiments, the surfactant is selected among the following compounds: E 400 alginic acid, E401 sodium alginate, E402 potassium alginate, E403 ammonium alginate, E404 calcium alginate, E430 polyoxyethene (8) stearate, E431 polyoxyethene (40) stearate, E432 polyoxyethene (20) sorbitan monolaurate (polysorbate 20), E433 polyoxyethene (20) sorbitan monooleate (polysorbate 80), E434 polyoxyethene (20) sorbitan monopalmitate (polysorbate 40), E435 polyoxyethene (20) sorbitan monostearate (polysorbate 60), E436 polyoxyethene (20) sorbitan tristearate (polysorbate 65), E470a sodium, potassium and calcium salts of fatty acids, E470b magnesium salts of fatty acids, E471 mono- and diglycerides of fatty acids (glyceryl monostearate, glyceryl distearate) and 10 other monoglycerides of fatty acids and diglycerides of fatty acids, E472 acetic acid esters of mono- and diglycerides of fatty acids, E472b lactic acid esters of mono- and diglycerides of fatty acids, E472c citric acid esters of mono- and diglycerides of fatty acids, E472d tartaric acid esters of mono- and diglycerides of fatty acids, E472e mono- and diacetyl tartaric acid esters of mono- and diglycerides of fatty acids, E472f mixed acetic and tartaric acid esters of mono- and diglycerides of fatty acids, E472g succinylated monoglycerides, E473 sucrose esters of fatty acids, E474 sucroglycerides, E475 polyglycerol esters of fatty acids, E476 polyglycerol polyricinoleate, E477 propane-1,2-diol esters of fatty acids, propylene glycol esters of fatty acids, E478 lactylated fatty acid esters of glycerol and propane-1, E479b thermally oxidized soya bean oil interacted with mono- and diglycerides of fatty acid, E480 dioctyl sodium 20 sulphosuccinate, E481 sodium stearoyl-2-lactylate, E482 calcium stearoyl-2-lactylate, E483 stearyl tartrate, E484 stearyl citrate, E485 sodium stearoyl fumarate, E486 calcium stearoyl fumarate, E487 sodium laurylsulphate, E488 ethoxylated mono- and di-glycerides, E489 methyl glucoside-coconut oil ester, E490 propane-1,2-diol, E491 sorbitan monostearate, E492 sorbitan tristearate, E493 sorbitan monolaurate, E494 sorbitan monooleate, E495 sorbitan 25 monopalmitate, E496 sorbitan trioleate, E497 polyoxypropylene-polyoxyethylene polymers and E498 partial polyglycerol esters of polycondensed fatty acids of castor oil. The term fatty acid includes any natural saturated fatty acids, monounsaturated fatty acids and polyunstaturated fatty acids and mixtures thereof.

In some embodiments, the surfactant or a surfactant mixture that has a HLB value of 30 from 1 to 20. The HLB (Hydrophilic Lipophilic Balance) value for a given surfactant is measure of the degree to which the surfactant is hydrophilic or lipophilic. The figure is dependent on which functional groups that are present in the surfactant molecule and where in the

molecule these functional groups are located. Surfactants with HLB value of less than 10 are soluble in lipids, while surfactants with HLB values higher than 10 are soluble in water. The HLB values of the various surfactants are available from various commercial and scientific sources; see for example Surfactants Classified by HLB Numbers on sigmaaldrich.com or basic teaching books in pharmaceutical sciences like A.T. Florence and D. Attwood: Physicochemical Principles of Pharmacy, Pharmaceutical Press, 2004 on page 240. The HLB value for some preferred surfactants according to the present invention are: mono-and diglycerides (HLB = appr.2-5 (depending on ratio, the more diglyceride the lower HLB value)), sorbitan esters HLB values around 4-5 (sorbitan oleate HLB = 4.3, sorbitan monostearate HLB = 4.7, sorbitan 10 stearate HLB = 4.7) and polysorbates HLB values around 15.

In some preferred embodiments, the surfactant is selected among mono- and diglycerides of fatty acids, sorbitan esters with fatty acids and polysorbates or mixtures thereof. In some embodiments, the surfactant is not a phospholipid and most preferably is not a naturally occurring phospholipid. In some embodiments, the surfactant is not a triglyceride and most preferably is not a naturally occurring triglyceride. In some embodiments, the surfactant is not a free fatty acid and most preferably is not a naturally occurring free fatty acid. In some preferred embodiments, the surfactant is not a salt or ester of EPA, DHA or other long chain (greater than 20 carbons) omega-3 fatty acid.

### 3) Tablets

Another aspect of the present invention relates to tablets formed from the powders described above. As described above, in some embodiments, the dry powders of the present invention are tabletable powders. In some embodiments, the dry powders of the present invention can be tableted using standard tabletting equipment producing more than 10,000 tablets per hour and the tablets can be prepared continuously for hours. In some preferred 25 embodiments, the tablets have a crushing strength of greater than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 kN, or from about 3 to 50, 3 to 40, 3 to 30, 3 to 20, 5 to 50, 5 to 40, 5 to 30, 5 to 20, 5 to 10, 7 to 50, 7 to 40, 7 to 30, 7 to 20, 10 to 50, 10 to 40, 10 to 30, or 10 to 20 kN.

In some embodiments, the tablets of the present invention comprise an oil component and beta-cyclodextrin in a defined ratio which may preferably be expressed as a 30 weight/weight (w/w) percentage of the oil component in the powder. In some

embodiments, the tablets of the present invention therefore comprise from 5% to 40%, 10% to 40%, 20% to 40%, 30% to 40%, 5% to 35%, 10% to 35%, 20% to 35%, 25% to 35%, 30% to 35%, at least 5%, at least 10%, at least 20%, at 30% or at least 35% w/w of an oil component, wherein w/w refers to the total weight of the oil component to the total weight of the tablet.

5        In some embodiments, the oil component preferably comprises one or more omega-3 fatty acids or derivatives thereof. In some embodiments, the one or more omega-3 fatty acids or derivatives thereof are selected from omega-3 triglycerides, omega-3 ethyl esters, free omega-3 acids and/or pharmaceutically acceptable or food acceptable quality omega-3 fatty acid salts, alone or in combination. In some embodiments, one or more of these omega 10 3 fatty acids and derivatives thereof are the main omega-3 components used to prepare the dry powder. In some embodiments, the one or more omega-3 fatty acids or derivatives thereof are selected from omega-3 triglycerides, omega-3 ethyl esters, free omega-3 acids and/or pharmaceutically acceptable or food acceptable quality omega-3 fatty acid salts, alone or in combination. In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are the main omega-3 components in the dry powder. In some 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999 10000 10005 10010 10015 10020 10025 10030 10035 10040 10045 10050 10055 10060 10065 10070 10075 10080 10085 10090 10095 10099 10100 10101 10102 10103 10104 10105 10106 10107 10108 10109 10110 10111 10112 10113 10114 10115 10116 10117 10118 10119 10120 10121 10122 10123 10124 10125 10126 10127 10128 10129 10130 10131 10132 10133 10134 10135 10136 10137 10138 10139 10140 10141 10142 10143 10144 10145 10146 10147 10148 10149 10150 10151 10152 10153 10154 10155 10156 10157 10158 10159 10160 10161 10162 10163 10164 10165 10166 10167 10168 10169 10170 10171 10172 10173 10174 10175 10176 10177 10178 10179 10180 10181 10182 10183 10184 10185 10186 10187 10188 10189 10190 10191 10192 10193 10194 10195 10196 10197 10198 10199 101999 102000 102001 102002 102003 102004 102005 102006 102007 102008 102009 1020010 1020011 1020012 1020013 1020014 1020015 1020016 1020017 1020018 1020019 10200110 10200111

acceptable or food acceptable quality of omega-3 fatty acid salts. In some embodiments, the omega-3 fatty acids or derivatives are preferably selected from EPA and DHA and combinations thereof. In some embodiments, the omega 3 fatty acids and derivatives thereof comprise more EPA than DHA (i.e., the ratio of EPA: DHA is greater than 1:1). In some 5 embodiments, the omega 3 fatty acids and derivatives thereof comprise more DHA than EPA (i.e., the ratio of DHA: EPA is greater than 1:1). In some embodiments, the omega 3 fatty acids and derivatives thereof (e.g., triglycerides, ethyl esters, free acids or salts thereof, alone or in combination) comprise are enriched for EPA, e.g., more than 90% w/w of the total omega 3 fatty acids and derivatives thereof in the powder is EPA where the w/w is the weight 10 of EPA per total weight of fatty acids in the powder. In some embodiments, the omega 3 fatty acids and derivatives thereof (e.g., triglycerides, ethyl esters, or free acids) are enriched for DHA, e.g., more than 90% w/w of the total omega 3 fatty acids and derivatives thereof in the powder is DHA where the w/w% is the weight of DHA per total weight of fatty acids in the powder. In some embodiments, the lipid component preferably comprises from about 30% 15 to 60% w/w EPA and/or DHA.

In some embodiments, the tablets may be further characterized according to their total omega-3 content. In some embodiments, the tablets of the present invention comprise more than 5 % w/w, more than 10% w/w, more than 15% w/w, more than 20% w/w, more than 25% w/w or more than 30% w/w of omega-3 triglycerides, omega-3 ethyl esters, free 20 omega-3 acids and/or pharmaceutically acceptable or food acceptable quality of omega-3 fatty acid salts where w/w refers to the total weight of the omega-3 triglycerides, omega-3 ethyl esters, free omega-3 acids and/or pharmaceutically acceptable or food acceptable quality of omega-3 fatty acid salts per the total weight of the tablet.

In some embodiments, the tablets of the present invention comprise a surfactant 25 (e.g., a diglyceride composition). In some embodiments, the w/w percent of the surfactant (e.g., a diglyceride composition) in the tablet may be less than the w/w percent of surfactant used to prepare the powder used to make the tablet, especially where the surfactant is water soluble. The surfactant or combination of surfactants is preferably included in the powder in a defined ratio as compared to the oil component.

Accordingly, in some embodiments, the tablets of the present invention comprise a surfactant in a defined ratio to the amount of the oil component in the tablet, preferably from 0.1% to 10% w/w, 0.1% to 20% w/w, 0.1% to 30% w/w, 1% to 10% w/w, 1% to 20% w/w, 1% to 30% w/w, 2% to 10% w/w, 2% to 20% w/w, 2% to 30% w/w, 5% to 10% w/w, 5% to 20% w/w, 5% to 30% w/w, 10% to 20% w/w, 10% to 30% w/w, 15% to 30% w/w, 18% to 30% w/w, 20% to 30% w/w, or 10% to 35% w/w surfactant or combination of surfactants, wherein w/w refers to the total weight of surfactant (or combination thereof) to the total weight of the oil component including the surfactant.

In some embodiments, the surfactant is a surfactant approved for use for preparation 10 of pharmaceutical products and or approved for use in food products. In some embodiments, the surfactant is a surfactant approved for use for preparation of pharmaceutical products. In some embodiments, the surfactant is a surfactant approved for use for preparation of approved for use in food products. In some embodiments, the surfactant is a ionic surfactant; preferably a negatively charged surfactant. In some embodiments, the surfactant is a non- 15 ionic surfactant. In some embodiments, the surfactant is a naturally occurring surfactant. In some embodiments, the surfactant is a surfactant produced synthetically or partly produced synthetically. In some embodiments, the surfactant is a derivative of a fatty acid. In some embodiments, the surfactant is a derivative of glycerol. In some embodiments, the surfactant is selected among substances that are permitted to be used as food additives for use within 20 the European Union, US or Asia. In some embodiments, the surfactant is selected among substances listed on the GRAS list. In some embodiments, the surfactant is selected among the following compounds: E 400 alginic acid, E401 sodium alginate, E402 potassium alginate, E403 ammonium alginate, E404 calcium alginate, E430 polyoxyethene (8) stearate, E431 polyoxyethene (40) stearate, E432 polyoxyethene (20) sorbitan monolaurate (polysorbate 25 20), E433 polyoxyethene (20) sorbitan monooleate (polysorbate 80), E434 polyoxyethene (20) sorbitan monopalmitate (polysorbate 40), E435 polyoxyethene (20) sorbitan monostearate (polysorbate 60), E436 polyoxyethene (20) sorbitan tristearate (polysorbate 65), E470a sodium, potassium and calcium salts of fatty acids, E470b magnesium salts of fatty acids, E471 mono- and diglycerides of fatty acids (glyceryl monostearate, glyceryl distearate) and 30 other monoglycerides of fatty acids and diglycerides of fatty acids, E472 acetic acid esters of mono- and diglycerides of fatty acids, E472b lactic acid esters of mono- and diglycerides of fatty acids, E472c citric acid esters of mono- and diglycerides of fatty acids, E472d tartaric acid

esters of mono- and diglycerides of fatty acids, E472e mono- and diacetyl tartaric acid esters of mono- and diglycerides of fatty acids, E472f mixed acetic and tartaric acid esters of mono- and diglycerides of fatty acids, E472g succinylated monoglycerides, E473 sucrose esters of fatty acids, E474 sucroglycerides, E475 polyglycerol esters of fatty acids, E476 polyglycerol 5 polyricinoleate, E477 propane-1,2-diol esters of fatty acids, propylene glycol esters of fatty acids, E478 lactylated fatty acid esters of glycerol and propane-1, E479b thermally oxidized soya bean oil interacted with mono- and diglycerides of fatty acid, E480 dioctyl sodium sulphosuccinate, E481 sodium stearoyl-2-lactylate, E482 calcium stearoyl-2-lactylate, E483 10 stearyl tartrate, E484 stearyl citrate, E485 sodium stearoyl fumarate, E486 calcium stearoyl fumarate, E487 sodium laurylsulphate, E488 ethoxylated mono- and di-glycerides, E489 methyl glucoside-coconut oil ester, E490 propane-1,2-diol, E491 sorbitan monostearate, E492 sorbitan tristearate, E493 sorbitan monolaurate, E494 sorbitan monooleate, E495 sorbitan monopalmitate, E496 sorbitan trioleate, E497 polyoxypropylene-polyoxyethylene polymers and E498 partial polyglycerol esters of polycondensed fatty acids of castor oil. The term fatty acid include any natural saturated fatty acids, monounsaturated fatty acids and 15 polyunsaturated fatty acids and mixtures thereof.

In some embodiments, the surfactant or a surfactant mixture that has a HLB value of from 1 to 20. The HLB (Hydrophilic Lipophilic Balance) value for a given surfactant is measure of the degree to which the surfactant is hydrophilic or lipophilic. The figure is dependent on 20 which functional groups that are present in the surfactant molecule and where in the molecule these functional groups are located. Surfactants with HLB value of less than 10 are soluble in lipids, while surfactants with HLB values higher than 10 are soluble in water. The HLB values of the various surfactants are available from various commercial and scientific sources; see for example Surfactants Classified by HLB Numbers on sigmaaldrich.com or basic 25 teaching books in pharmaceutical sciences like A.T. Florence and D. Attwood: Physicochemical Principles of Pharmacy, Pharmaceutical Press, 2004 on page 240. The HLB value for some preferred surfactants according to the present invention are: mono-and diglycerides (HLB = appr.2-5 (depending on ratio, the more diglyceride the lower HLB value)), sorbitan esters HLB values around 4-5 (sorbitan oleate HLB = 4.3, sorbitan monostearate HLB = 4.7, sorbitan 30 stearate HLB = 4.7) and polysorbates HLB values around 15.

In some preferred embodiments, the surfactant is selected among mono- and diglycerides of fatty acids, sorbitan esters with fatty acids and polysorbates or mixtures thereof. In some embodiments, the surfactant is not a phospholipid and most preferably is not a naturally occurring phospholipid. In some embodiments, the surfactant is not a 5 triglyceride and most preferably is not a naturally occurring triglyceride. In some embodiments, the surfactant is not a free fatty acid and most preferably is not a naturally occurring free fatty acid. In some preferred embodiments, the surfactant is not a salt or ester of EPA, DHA or other long chain (greater than 20 carbons) omega-3 fatty acid. The more preferred surfactants in tablets are diglycerides and the most preferred surfactants are 10 diglycerides where one or more of the acids are omega-3 fatty acids. The typically most preferred diglycerides comprise of a mixture of diglyceride compounds where the fatty acid components in the mixture of diglyceride molecules can be saturated, monounsaturated and/or polyunsaturated, including omega-3 fatty acids like EPA and DHA.

In some embodiments, the tablets are coated. Suitable coatings include, but are not 15 limited to, polyvinyl acetate, methyl acrylate-methacrylic acid copolymers, cellulose acetate phthalate (CAP), cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylic acid copolymers, cellulose acetate trimellitate, and sodium alginate.

20

## EXAMPLES

### **Example 1. Preparation of 30:70 triglyceride:beta-cyclodextrin complexes with diglycerides.**

Beta-cyclodextrin (1000g) was suspended in water at room temperature. A mixture of 25 EPA and DHA (60% w/w) and various fatty acids as triglycerides, diglycerides and monoglycerides (430 g) was added. The mixture was stirred for 1 hour. The water was evaporated. The product was off-white, tabletable powder.

### **Example 2. Preparation of 30:70 triglyceride:beta-cyclodextrin complexes prepared with 7% diglycerides**

The product was prepared as in example 1 with oil with glyceride composition (triglycerides/diglycerides/monoglycerides) as 91/7/1 area %. The product was a slurry with obvious oil layers, it was not possible to prepare dry powders from this mixture.

5    **Example 3. Preparation of 30:70 triglyceride:beta-cyclodextrin complexes prepared with 19 area % diglycerides.**

The product was prepared as in example 1 with oil with glyceride composition (triglycerides/diglycerides/monoglycerides) as 80/19/1 area %.

The product was dry, off-white to yellow powder. The powder was tabletable.

10    **Example 4. Preparation of 30:70 triglyceride:beta-cyclodextrin complexes prepared with 24 area % diglycerides.**

The product was prepared as in example 1 with oil with glyceride composition (triglycerides/diglycerides/monoglycerides) as 74/25/1 area %.

The product was dry, off-white powder. The powder was directly tabletable.

15    **Example 5. Preparation of 30:70 triglyceride:beta-cyclodextrin complexes prepared with 32 area % diglycerides.**

The product was prepared as in example 1 with oil with glyceride composition (triglycerides/diglycerides/monoglycerides) as 67/32/1 area %.

The product was dry, off-white powder. The powder was directly tabletable.

20    **Example 6. Preparation of 30:70 triglyceride:beta-cyclodextrin complexes prepared with 34 area % diglycerides.**

The product was prepared as in example 1 with oil with glyceride composition (triglycerides/diglycerides/monoglycerides) as 65/34/1 area %.

The product was dry, off-white powder. The powder was directly tabletable.

**Example 7. Tablets prepared from 30:70 triglyceride:beta-cyclodextrin complexes prepared with 27 area % diglycerides.**

Tablets comprising 96% (w/w) triglyceride:beta-cyclodextrin complexes prepared from oil with glyceride composition (triglycerides/diglycerides/monoglycerides) as 74/25/1 area % 5 was prepared in a conventional tabletting machine.

The tablets achieved a crushing strength of 9.1 kN.

**Example 8. Preparation of triglyceride:beta-cyclodextrin powder with spray granulation**

The powder was prepared as in example 1, the method for water evaporation was 10 spray granulation. The powder comprised of rounded particles with particle size distribution between 50-650 microns. The powder was directly tablettable.

**Example 9. Preparation of 30:70 triglyceride:beta-cyclodextrin complexes with different content of diglyceride (DG) optionally added a surfactant.**

The powder products were prepared as in example 1, spray granulated when 15 complexes were achieved and tableted.

**Example 10. Results for powder and tabletting experiments.**

The following Table provides results from experiments in which varying levels of surfactants, including diglycerides and other added surfactants, were used in powder formulations.

20 The first 10 experiments demonstrate that triglyceride omega-3 oil with a low content of diglycerides (8%) with added surfactants (1% or 10%) did not result in a powder for direct compaction (DC).

25 The next experiment shows that triglyceride omega-3 oil with relative high content of diglycerides (27%) result in powder for direct compaction. The next 3 experiments show that addition of surfactants to the composition results in a minor reduction of the crushing strength of the tablets, however, the powders were still tablettable.

The final 3 experiments have been performed with three different ethyl ester oils.

EE60 comprise 60 % omega-3, EE5325 comprise 33% EPA and 23%DHA and EE4020 comprise 40% EPA and 20% DHA. The results show that all ethyl ester oil composition tested, pain and with surfactants(s) formed powder that were directly compactable.

5 A control tablet experiment using a triglyceride omega-3 comprising 69% diglyceride showed lower crushing strength than comparative tablets comprising appr. 30% diglyceride (same oil loading in both tablets).

| Oil          |          |           | Surfactants        |      |        | Powder   | Tablets                |                |
|--------------|----------|-----------|--------------------|------|--------|----------|------------------------|----------------|
| Raw material | Oil load | MG/DG /TG | Surfactant         | HLB  | Amount |          | Crushing strength (kN) | Friability (%) |
| TG3322       | 30%      | 1/8/91    | Span 85            | 1.8  | 1%     | No       | -                      | -              |
|              |          |           | Tween 40           | 15.6 | 1%     | No       | -                      | -              |
|              |          |           | Tween 40+Span 85   | 9.2  | 1%     | No       | -                      | -              |
|              |          |           | Span 20            | 8.6  | 1%     | No       | -                      | -              |
|              |          |           | Span 80            | 4.3  | 1%     | No       | -                      | -              |
|              |          |           | Tween 80           | 15   | 1%     | No       | -                      | -              |
|              |          |           | Tween 60           | 14.9 | 1%     | No       | -                      | -              |
|              |          |           | Span 85            | 1.8  | 10%    | No       | -                      | -              |
|              |          |           | Tween 40           | 15.6 | 10%    | No       | -                      | -              |
|              |          |           | Span 20 + Tween 40 | 12.1 | 10%    | No       | -                      | -              |
|              |          |           |                    |      |        |          |                        |                |
| Oil          |          |           | Surfactants        |      |        | Powder   | Tablets                |                |
| Raw material | Oil load | MG/DG /TG | Surfactant         | HLB  | Amount |          | Crushing strength (kN) | Friability (%) |
| TG3322       | 30%      | 1/27/69   | None               | -    | -      | DC grade | 9.1                    | 99.9           |
|              |          |           | Span 85            | 1.8  | 1%     | DC grade | 8.7                    | 99.9           |
|              |          |           | Tween 40           | 15.6 | 0.1%   | DC grade | 7.6                    | 99.9           |
|              |          |           | Tween 40+Span 85   | 9.2  | 1%+1%  | DC grade | 7.6                    | 99.9           |
|              |          |           |                    |      |        |          |                        |                |
| Oil          |          |           | Surfactants        |      |        | Powder   | Tablets                |                |
| Raw material | Oil load | MG/DG /TG | Surfactant         | HLB  | Amount |          | Crushing strength (kN) | Friability (%) |
| EE60         | 30%      | -         | None               | -    | -      | DC grade | 8.6                    | 99.9           |

|        |     |   |                       |     |       |             |     |      |
|--------|-----|---|-----------------------|-----|-------|-------------|-----|------|
| EE3525 | 30% | - | Tween 40 +<br>Span 85 | 9.2 | 1%+1% | DC<br>grade | 5.4 | 99.8 |
| EE4020 | 30% | - | Span 85               | 1.8 | 0.5 % | DC<br>grade | 6.9 | 99.9 |

**Claims:**

1. A composition comprising:

a dry powder comprising beta-cyclodextrin in an amount of from 60% to 90% w/w of said powder and a lipid component in an amount of from about 10% to 40% w/w of said powder, wherein said lipid component comprises an omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, wherein said omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty acids at a concentration of from 10% to 99% w/w of the fatty acids in said omega-3 triglycerides, wherein said lipid component is characterized as having a surfactant content of from about 10% to 35% w/w of said lipid component, wherein said surfactant is a diglyceride of fatty acids.

2. The composition of claim 1, wherein said omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty acids at a concentration of from 10% to 70% w/w of the fatty acids in said omega-3 triglycerides.

3. The composition of claim 1, wherein said omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty acids at a concentration of from 30% to 60% w/w of the fatty acids in said omega-3 triglycerides.

20 4. The composition of claim 1, wherein said omega-3 triglycerides are a marine oil, preferably wherein said marine oil is selected from the group consisting of fish oil, squid oil and algal oil.

25 5. The composition according to any one of claims 1 to 4, wherein said diglycerides of fatty acids comprise a mixture of diglyceride compounds wherein the fatty acid components of the diglycerides compounds are selected from polyunsaturated fatty acids.

6. The composition according to claim 5, wherein said polyunsaturated fatty acids are omega-3 fatty acids, and wherein said omega-3 fatty acids are selected from EPA and DHA..

7. A tableted lipid formulation comprising beta-cyclodextrin in a concentration of from 60% to 90% w/w of said tablet and a lipid component in a concentration of from 10% to 40% w/w of said tablet, wherein said lipid component comprises an omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, wherein

5 said omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, comprises EPA and DHA fatty acids at a concentration of from 10% to 99% w/w of the fatty acids in said omega-3 triglycerides, wherein said lipid component is characterized as having a diglyceride content of from 10% to 35% w/w of said lipid component.

10 8. The tableted lipid formulation of claim 7, wherein said omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty acids at a concentration of from 10% to 70% w/w of the fatty acids in said omega-3 triglycerides.

15 9. The tableted lipid formulation of claim 7, wherein said omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty acids at a concentration of from 30% to 60% w/w of the fatty acids in said omega-3 triglycerides.

20 10. The tableted lipid formulation of claim 7, wherein said omega-3 triglycerides are a marine oil, preferably wherein said marine oil is selected from the group consisting of fish oil, squid oil and algal oil.

11. The tableted lipid formulation of claim 7, wherein said diglycerides of fatty acids comprise a mixture of diglyceride compounds wherein the fatty acid components of the diglycerides compounds are selected from polyunsaturated fatty acids.

25 12. The tableted lipid formulation of claim 11, wherein said polyunsaturated fatty acids are omega-3 fatty acids, wherein said omega-3 fatty acids are selected from EPA and DHA.

13. The tableted lipid formulation according to any one of claims 7 to 12, wherein the tableted formulation is coated, preferably wherein the tableted formulation is coated with an agent selected from the group consisting of polyvinyl acetate, methyl acrylate-methacrylic acid copolymers, cellulose acetate phthalate (CAP), cellulose acetate succinate, 5 hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylic acid copolymers, cellulose acetate trimellitate, and sodium alginate.

14. A process for making a tabletable lipid powder comprising:

10 combining an aqueous solution of beta-cyclodextrin with a lipid component in an amount of from 10% to 40% w/w of said beta-cyclodextrin said solution, wherein said lipid component comprises an omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides, wherein said omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty 15 acids at a concentration of from 10% to 99% w/ of the fatty acids in said omega-3 triglycerides, wherein said lipid component comprises one or more surfactants at a concentration of from 10% to 35% w/w of said lipid component, wherein said surfactant is a diglyceride of fatty acids;

20 mixing said aqueous solution of beta-cyclodextrin and said lipid component to provide a mixture; and

removing water from said mixture to provide a dry powder, preferably by spray granulating.

**Omegatri AS**

**Patent Attorneys for the Applicant/Nominated Person**  
**SPRUSON & FERGUSON**